Emerging developments of chemoradiotherapy in stage III NSCLC

Nature Reviews Clinical Oncology

Volumn 9, Issue 10, 2012, Pages 591-598

  Price, Allan ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEFITINIB; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; MITOMYCIN; NAVELBINE; NEDAPLATIN; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE; VINDESINE;

ADJUVANT THERAPY; ADVERSE OUTCOME; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPARATIVE EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; ONSET AGE; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING;

EID: 84867099936     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.135     Document Type: Review

References (93)

1. Liu, B. Q. et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ 317, 1411-1422 (1998).
2. van Meerbeeck, J. P. & Surmont, V. F. Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments. Lung Cancer 65, 257-267 (2009).
3. O'Rourke, N., Roqué i Figuls, M., Farré Bernadó, N. & Macbeth, F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database of Systematic Reviews, Issue 16. Art. No.: CD002140. http://dx.doi/org/10.1002/14651858.CD002140.pub3
4. Aupérin, A. et al. Meta-analysis of concomitant versus sequential radio-chemotherapy in locally advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 2181-2190 (2010).
5. Mauguen, A. et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J. Clin. Oncol. 30, 2788-2797 (2012).
6. Robinson, L. A., Ruckdeschel, J. C., Wagner, H. Jr & Stevens, C. W. American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (Suppl. 3), 243S-265S (2007).
7. Jett, J. R., Schild, S. E., Keith, R. L. & Kesler, K. A. American College of Chest Physicians. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 (Suppl. 3), 2665-2765 (2007).
8. van Meerbeeck, J. P. et al. on behalf of the European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. JNCI J. Natl Cancer Inst. 99, 442-450 (2007).
9. Albain, K. S. et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374, 379-386 (2009).
10. Subramanian, J. et al. Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis. J. Thorac. Oncol. 5, 23-28 (2010).
11. De Ruysscher, D. et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann. Oncol. 20, 98-102 (2009).
12. Hardy, D., Liu, C.-C., Cormier, J. N., Xia, R. & Du, X. L. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann. Oncol. 21, 1825-1833 (2010).
13. Davidoff, A. J., Gardner, J. F., Seal, B. & Edelman, M. J. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. J. Thorac. Oncol. 6, 934-941 (2011).
14. Coate, L. E. et al. Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J. Thorac. Oncol. 6, 537-544 (2011).
15. Phernambucq, E. C. J. et al. Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity. Ann. Oncol. 22, 132-138 (2011).
16. Semrau, S., Klautke, G., Virchow, J. C., Kundt, G. & Fietkau, R. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy. Respir. Med. 102, 210-218 (2008).
17. Schild, S. E. et al. for the North Central Cancer Treatment Group. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer 110, 363-368 (2007).
18. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311, 899-909 (1995).
19. Cox, J. D. Are the results of RTOG 0617 mysterious? Int. J. Radiat. Oncol. Biol. Phys. 82, 1042-1044 (2012).
20. US National Library of Medicine. Clinicaltrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00533949 (2011).
21. Perez, C. A. et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45, 2744-2753 (1980).
22. Maguire, J. et al. SOCCAR: sequential or concurrent chemotherapy and hypofractionated accelerated radiotherapy in inoperable stage III NSCLC [abstract 7039]. J. Clin. Oncol. 29 (Suppl.) (2011).
23. Saunders, M. et al. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. CHART Steering Committee. Lancet 350, 161-165 (1997).
24. Kratz, J. R. et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 379, 823-832 (2012).
25. National Cancer Institute at the National Institutes of Health. Clinical Trials Search Results [online], http://www.cancer.gov/clinicaltrials/search/ results?protocolsearchid=10268411.
26. Belani, C. P. et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J. Clin. Oncol. 23, 5883-5891 (2005).
27. O'Rourke, N. & Edwards, R. Lung cancer treatment waiting times and tumour growth. Clin. Oncol. (R. Coll. Radiol.) 12, 141-144 (2000).
28. Masters, G. A. et al. A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. Lung Cancer 74, 258-263 (2011).
29. Vokes, E. E. et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J. Clin. Oncol. 20, 4191-4198 (2002).
30. Socinski, M. A. et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J. Clin. Oncol. 26, 2457-2463 (2008).
31. Yamamoto, N. et al. Phase III study comparing second-and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J. Clin. Oncol. 28, 3739-3745 (2010).
32. Takeda, K. et al. A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706. Jpn J. Clin. Oncol. 41, 25-31 (2011).
33. Oshita, F. et al. Phase II study of nedaplatin and irinotecan with concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer. Br. J. Cancer 103, 1325-1330 (2010).
34. Jalal, S. I. et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann. Oncol. 23, 1730-1738 (2012).
35. Kelly, K. et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J. Clin. Oncol. 26, 2450-2456 (2008).
36. Segawa, Y. et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J. Clin. Oncol. 28, 3299-3306 (2010).
37. Takigawa, N. et al. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007. J. Thorac. Oncol. 6, 1087-1091 (2011).
38. Senan, S. et al. A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. Ann. Oncol. 22, 553-558 (2011).
39. Govindan, R. et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J. Clin. Oncol. 29, 3120-3125 (2011).
40. Gadgeel, S. M. et al. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. J. Thorac. Oncol. 6, 927-933 (2011).
41. US National Library of Medicine. Clinicaltrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00686959 (2012).
42. Ichinose, Y. et al. S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer: a multi-institutional phase II trial (West Japan Thoracic Oncology Group 3706). J. Thorac. Oncol. 6, 2069-2075 (2011).
43. Vokes, E. E. et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J. Clin. Oncol. 25, 1698-1704 (2007).
44. Stinchcombe, T. E. et al. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J. Thorac. Oncol. 4, 1117-1125 (2009).
45. Harada, H. et al. Comparison of chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small cell lung cancer. Int. J. Clin. Oncol. 14, 507-512 (2009).
46. Wang, L. et al. Randomized phase II study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer 77, 89-96 (2012).
47. Martel, M. K. et al. Estimation of tumor control probability model parameters from 3D dose distributions of non-small cell lung cancer patients. Lung Cancer 24, 31-37 (1999).
48. Partridge, M., Ramos, M., Sardaro, A. & Brada, M. Dose escalation for non-small cell lung cancer: analysis and modelling of published literature. Radiother. Oncol. 99, 6-11 (2011).
49. Fenwick, J. D. et al. Escalation and intensification of radiotherapy for stage III non-small cell lung cancer: opportunities for treatment improvement. Clin. Oncol. (R. Coll. Radiol.) 21, 343-360 (2009).
50. van Baardwijk, A. et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J. Clin. Oncol. 28, 1380-1386 (2010).
51. Lee, C. B. et al. Late complications of high-dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer. J. Thorac. Oncol. 4, 74-79 (2009).
52. Salama, J. K. et al. Pulmonary toxicity in stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. Int. J. Radiat. Oncol. Biol. Phys. 81, e269-274 (2011).
53. Cuzick, J. et al. Overview of randomized trials of postoperative adjuvant radiotherapy in breast cancer. Cancer Treat Rep. 71, 15-29 (1987).
54. Rutqvist, L. E., Lax, I., Fornander, T. & Johansson, H. Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 22, 887-896 (1992).
55. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352, 257-263 (1998).
56. Allen, A. M. et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 65, 640-645 (2006).
57. Minami-Shimmyo, Y. et al. Risk factors for treatment-related death associated with chemotherapy and thoracic radiotherapy for lung cancer. J. Thorac. Oncol. 7, 177-182 (2012).
58. Bradley, J. D., Wahab, S., Lockett, M. A., Perez, C. A. & Purdy, J. A. Elective nodal failures are uncommon in medically inoperable patients with stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int. J. Radiat. Oncol. Biol. Phys. 56, 342-347 (2003).
59. Yuan, S. et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am. J. Clin. Oncol. 30, 239-244 (2007).
60. Hatton, M. et al. Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (CHART) for patients with locally advanced inoperable non-small-cell lung cancer: the MRC INCH randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 81, 712-718 (2011).
61. Baumann, M. et al. Final results of the randomized phase III CHARTWELL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother. Oncol. 100, 76-85 (2011).
62. De Ruysscher, D. et al. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: a prospective population-based study. Radiother. Oncol. 102, 228-233 (2012).
63. Krause, M. et al. Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. Radiother. Oncol. 76, 162-167 (2005).
64. Eriksen, J. G. et al. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiother. Oncol. 72, 275-282 (2004).
65. Koukourakis, M. I. et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2α and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J. Clin. Oncol. 24, 727-735 (2006).
66. De Ruysscher, D., Nestle, U., Jeraj, R. & Macmanus, M. PET scans in radiotherapy planning of lung cancer. Lung Cancer 75, 141-145 (2012).
67. US National Library of Medicine. Clinicaltrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00697333 (2012).
68. Feng, M. et al. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int. J. Radiat. Oncol. Biol. Phys. 73, 1228-1234 (2009).
69. Aerts, H. J. et al. Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer 75, 73-76 (2012).
70. Liao, Z. X. et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 76, 775-781 (2010).
71. Shumway, D. et al. Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. Lung Cancer 74, 446-450 (2011).
72. Korreman, S., Persson, G., Nygaard, D., Brink, C. & Juhler-Nøttrup, T. Respiration-correlated image guidance is the most important radiotherapy motion management strategy for most lung cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 83, 1338-1343 (2012).
73. Giraud, P. et al. Respiratory gating techniques for optimization of lung cancer radiotherapy. J. Thorac. Oncol. 6, 2058-2068 (2011).
74. Grutters, J. P. et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother. Oncol. 95, 32-40 (2010).
75. Chang, J. Y. et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer 117, 4707-4713 (2011).
76. Ready, N. et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. J. Thorac. Oncol. 5, 1382-1390 (2010).
77. Nieder, C., Pawinski, A., Dalhaug, A. & Andratschke, N. A review of clinical trials of cetuximab combined with radiotherapy for non-small cell lung cancer. Radiat. Oncol. 7, 3 (2012).
78. Hallqvist, A. et al. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite-a phase II study from the Swedish Lung Cancer Study Group. Lung Cancer 71, 166-172 (2011).
79. Mutter, R. et al. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. Clin. Cancer Res. 15, 2158-2165 (2009).
80. Lind, J. S., Senan, S. & Smit, E. F. Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer. J. Clin. Oncol. 30, e104-108 (2012).
81. Spigel, D. R. et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J. Clin. Oncol. 28, 43-48 (2010).
82. Butts, C. et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J. Clin. Oncol. 23, 6674-6681 (2005).
83. Butts, C. et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J. Cancer Res. Clin. Oncol. 137, 1337-1342 (2011).
84. US National Library of Medicine. Clinicaltrials.gov [online], http://www.clinicaltrials.gov/ct2/show/NCT00409188 (2012).
85. Curran, W. J. Jr, Schiller, J. H., Wolkin, A. C. & Comis, R. L. Scientific Leadership Council in Lung Cancer of the Coalition of Cancer Cooperative Groups. Addressing the current challenges of non-small-cell lung cancer clinical trial accrual. Clin. Lung Cancer 9, 222-226 (2008).
86. Price, A., Dixon, B., Erridge, S. C., Mohammed, N. GRiN: a trial and tribulation in respiratory radiotherapy research. Clin. Oncol. (R. Coll. Radiol.) 17, 328-331 (2005).
87. Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the community code relating to medicinal products for human use. Off. J. Eur. Union 47 (L136), 34-57.
88. Stratton, M. R. Exploring the genomes of cancer cells: progress and promise. Science 331, 1553-1558 (2011).
89. Berry, D. A. Adaptive clinical trials in oncology. Nat. Rev. Clin. Oncol. 9, 199-207 (2012).
90. Strebhardt, K. & Ullrich, A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer 8, 473-480 (2008).
91. Overgaard, J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res. 6, 509-518 (1994).
92. Radiotherapy and hyperbaric oxygen. Report of a Medical Research Council Working Party. Lancet 2, 881-884 (1978).
93. Medicines and Healthcare products Regulatory Agency. Clinical trials for medicines: Safety reporting-SUSARs [online], http://www.mhra.gov.uk/ Howweregulate/Medicines/Licensingofmedicines/Clinicaltrials/Safetyreporting- SUSARsandASRs/index.htm (2012).